HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-0295v1 30/9/2181    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Umpierrez, G. E. Articles by Mejia, R. Search for Related Content PubMed PubMed Citation Articles by Umpierrez, G. E. Articles by Mejia, R. Social Bookmarking                What's this?

RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2 Trial)

¹Emory University School of Medicine, Atlanta, Georgia
²University of Miami School of Medicine, Miami, Florida

geumpie{at}emory.edu

ABSTRACT

Background:Few studies have focused on the optimal management of hyperglycemia in non-ICU patients with type 2 diabetes mellitus.

Research Design and Methods:Prospective, multicenter randomized trial to compare the efficacy and safety of a basal/bolus insulin regimen to sliding scale regular insulin (SSI) in patients with type 2 diabetes. A total of 130 insulin-naïve patients were randomized to receive glargine and glulisine (n= 65) or a standard SSI protocol (n= 65). Glargine was given once daily and glulisine before meals at a starting dose of 0.4 U/kg/day for BG 140-200 mg/dL or 0.5 U/kg/day for BG 201-400 mg/dL. SSI was given 4 times/day for BG >140 mg/dL.

Results:The mean admission blood glucose was 229 ± 6 mg/dL and hemoglobin A1C was 8.8 ± 2 %. A blood glucose target of < 140 mg/dl was achieved in 66% of patients in the glargine and glulisine group and 38% in the SSI. The mean daily blood glucose between groups ranged from 23 to 58 mg/dl, with an overall blood glucose difference of 27 mg/dL (p<0.01). Despite increasing insulin doses, 14% of patients treated with SSI remained with blood glucose > 240 mg/dl. There were no differences in the rate of hypoglycemia or length of hospital stay.

Conclusion:Treatment with insulin glargine and glulisine resulted significant improvement in glycemic control compared to the use of SSI alone. Our study indicates that a basal/bolus insulin regimen is preferred over SSI in the management of noncritically-ill, hospitalized patients with type 2 diabetes.

NCT registration Number:00394407

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Balasubramanyam, R. Nalini, C. S. Hampe, and M. Maldonado Syndromes of Ketosis-Prone Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 292 - 302. [Abstract] [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]

				A. E. Kitabchi and E. Nyenwe Sliding-Scale Insulin: More evidence needed before final exit? Diabetes Care, September 1, 2007; 30(9): 2409 - 2410. [Full Text] [PDF]